Document:

Exhibit 10.18

 

Collaboration
Agreement

 

This collaboration
agreement (the “Agreement”) is entered into and effective as of December 7, 2013 (the “Effective Date”),
by and between Stellar Biotechnologies Inc., a California corporation (“SBI”), and Amaran Biotechnology Inc.,
a Taiwan corporation (“ABI”). SBI and ABI are referred to individually herein from time to time as a “Party,”
and collectively as the “Parties.”

 

Whereas,
SBI owns certain patents, know-how and other intellectual property rights for keyhole limpet hemocyanin (“KLH”)
formulation and manufacturing; and

 

Whereas,
SBI is engaged in the business of designing, developing and manufacturing KLH for conjugated cancer vaccines; and

 

Whereas,
ABI is engaged in the business of designing, developing and manufacturing KLH-conjugated OBI-822 drug product candidate (OBI-822)
based on the specifications of its customers; and

 

Whereas,
SBI and ABI desire to collaborate, on a non-commercial basis, to develop KLH formulations meeting the product specifications agreed
on by the Parties in connection with the possible future manufacture and commercial sale of OBI-822 ;

 

Now,
therefore, for good and valuable consideration, the Parties agree as follows:

 

1.          Appendices.
The following appendices are attached to this Agreement, and are hereby incorporated as part of this Agreement:

 

			Appendix A – Table of Contents of Appendix B-X

 

Appendix B – Appendix B-X: Statement of Work

 

Appendix C – Nondisclosure Agreement

 

2.           Development.

 

2.1           Purpose.
The purpose of this collaboration is to develop and evaluate methods for the manufacture of ABI’s OBI-822 using Stellar cGMP
grade keyhole limpet hemocyanin (“Stellar cGMP grade KLH”) to meet the regulatory requirements and specifications
provided by ABI and agreed upon by the Parties, and to produce certain KLH reference standards required by ABI. Additionally, the
goal of the collaboration project is to significantly reduce ABI’s cost of KLH and improve the yields in the commercial manufacture
of OBI-822.

 

    	 	Page 1 of 10	 

     

    

  

2.2           Statement
of Work. SBI shall be responsible for the production and delivery of Stellar cGMP-grade KLH and non-GMP grade KLH manufactured
from aquaculture KLH in sub-unit forms (“Stellar KLH20-M”) for evaluation by ABI for suitability as a carrier
protein in OBI-822, and for method development, product formulation and process qualification for certain KLH reference standards
for evaluation by ABI. ABI shall be responsible for establishing the development objectives and product specifications. ABI may
assign work plan responsibilities to sub-contractors, including OBI Pharma, Inc. in accordance with Section 2.11 hereof. Whenever
required, these activities shall be performed in compliance with the U.S.A. Food and Drug Administration cGMP regulation guidelines
and with the objectives, specifications, milestones, schedule and deliverables as described in respective Statement of Work to
be attached as Appendix B-X.

 

2.3           Modifications
to Statement of Work. If the Parties desire any change in the specifications of products, the schedule or other aspects of
the collaboration, any such change shall be accomplished only by a written amendment to the respective Statement of Work. Any amendment
to any Statement of Work shall take effect no less than 30 days prior to the intended start date of each project contemplated by
that amended Statement of Work.

 

2.4           Deliverables.
On an ongoing basis (as available), SBI and ABI shall deliver to the other Party any and all test articles, data, and other documentation
as appropriate to permit prompt performance under this Agreement including summaries of data that such Party collects through its
testing of the intermediate or final test articles. All deliverables of test articles shall be delivered as mutually agreed upon
within the Timeline attached as Appendix B-X. All shipment of test articles between the Parties would be FCA (Incoterms
2000) to the receiving Party unless otherwise agreed upon in writing between the Parties in advance. All deliverables of test articles
shall be memorialized by a delivery confirmation that sets forth the nature and condition of the deliverables, the medium of delivery
and the date of delivery. The receiving Party shall countersign the delivery confirmation to indicate receipt of the contents described
therein.

 

2.5           Testing
of Deliverables. The deliverables under any Statement of Work will be inspected, tested, accepted, rejected, re-tested and
regression tested as required by the respective Statement of Work. In the event that any article delivered under this Agreement
is rejected by the receiving Party, reasons for rejection shall be stated in writing in reasonable detail and the delivering Party
shall use reasonable commercial efforts to correct any deficiencies or non-conformities, and resubmit the rejected items as promptly
as possible. Failure to provide notice of rejection in writing for any article within 14 (fourteen) business days after receipt
of a deliverable for which the Statement of Work does require acceptance testing, will constitute acceptance.

 

2.6           Standard
of Performance. SBI and ABI shall each devote such time and resources as reasonably necessary to timely accomplish the objectives
of this Agreement, and all services shall be accomplished in compliance with applicable laws and regulations. SBI and ABI shall
each perform its respective obligations, and shall fully cooperate and communicate with each other, in a reasonable and good faith
manner in order not to hinder or delay the services of the other Party, and in order to facilitate the prompt and satisfactory
completion of the Statement of Work. SBI and ABI shall each promptly notify the other in writing of any factor, occurrence or event
coming to its attention that may affect its ability to timely fulfill its obligations under this Agreement.

 

    	 	Page 2 of 10	 

     

    

  

2.7           Regulatory
Compliance. ABI shall carry out all quality and clinical research, testing and studies relating to vaccine formulations that
include SBI test articles as required to obtain all regulatory approvals needed to import, market, sell or use SBI test articles.
SBI shall consult with and assist ABI as reasonably requested in making any necessary submissions or filings for regulatory approval.
SBI and ABI will each follow its own standard operating procedures for quality control through this development project; provided,
however, that quality control procedures applied to SBI’ test article in vaccine, should be no lower than the U.S.A. Food
and Drug Administration Code of Federal Regulations, Title 21 (21 CFR) Part 820 Quality System Regulation procedures, as amended
from time to time.

 

2.8           Limitation
on Services. Except as specifically provided in the Statement of Work or otherwise in this Agreement, the Parties have no obligation
to provide research, development, support, training, maintenance, product enhancements, modifications or other services for the
benefit of the other. Any such services must be agreed in the Statement of Work, or written amendment to this Agreement, signed
by both Parties.

 

2.9           Designated
Representatives. The following individuals shall be the primary representatives to manage and implement the collaboration (the
“Representatives”). The Representatives may be substituted from time to time by the respective employing Party
following notice given to the other Party, and provided that the substituted Representative holds substantially similar authority.
Meetings or conference calls of the Representatives shall be held as needed (but at least once every two weeks) at a time and location
mutually acceptable to each Party, in order to evaluate performance, to discuss problems and to set goals. Additionally Representatives
may appoint such other persons as the Parties may determine appropriate to form a Joint Steering Committee to meet from time to
time, but no less than quarterly to review progress of the projects.

 

	 	SBI	 	ABI
	Name:	Catherine Brisson, Ph.D.	 	Yu Hung Chiu, Ph.D.
	Title:	Chief of Operations	 	Technical Consultant/Director
	Email:	cbrisson@stellarbiotech.com	 	yuhungchiu@amaran.com.tw
	Phone:	805-488-2147	 	858-232-3514
	Fax:	805-488-2889	 	 

 

2.10        Fees
and Expenses.

 

a.           Labor
Expense. ABI shall pay SBI a quarterly labor expense fee of US$45,000 (tax included) per calendar quarter based upon the needs
during the Agreement, pro-rated for partial quarters, to fund the equivalent of the burdened salary for one manufacturing scientist
and one technician required for the implementation of this Agreement (the “Labor Expense”). The Labor Expense
shall be due and payable on the first day of each calendar quarter with the first payment within 30 days of the Effective Date.
The Labor Expense can be renegotiated based upon the needs of the contract and can be extended, amended or terminated (60 days’
notice required).

 

b.           Direct
Cost Reimbursement. Subject to ABI’s prior approval in writing, ABI shall reimburse SBI for all direct costs for contract
expenses and specialty items specifically requested by ABI; and SBI shall reimburse ABI for all direct costs for contract expenses
and specialty items specifically requested by SBI in the execution of the provisions of this Agreement as specified in the work
plans of each respective Appendix B-X. 

 

    	 	Page 3 of 10	 

     

    

  

c.           Expenses.
Each Party shall be responsible for its own project expenses and payment schedules as agreed and provided above or specified in
Appendix B-X. Neither Party shall have any responsibility for the payment or reimbursement of any expenses incurred by the
other Party outside of the Statement of Work of this Agreement, unless specified by another agreement between the Parties.

 

2.11        Use
of Subcontractors. Either Party shall have the right to subcontract services under this Agreement to reasonably qualified subcontractors,
subject to (a) the other Party’s prior written consent, which shall not be unreasonably withheld, and (b) the subcontractor
signing an appropriate nondisclosure agreement equivalent to the Nondisclosure Agreement attached as Appendix C. However,
the subcontracting of any services shall not diminish the contractual responsibility hereunder of the Party entering into such
relationship. The notice required by this paragraph shall include the name, address, contact information, scope of the services
subcontracted, and other pertinent information. Notwithstanding the foregoing or any other term of this Agreement, ABI covenants
and agrees that it shall not transfer or make available to any third party any Stellar Materials (as defined below) without the
express prior written consent of SBI.

 

3.           Manufacture
and Supply.

 

3.1           KLH
Supply Agreement. In the event that the Parties determine to proceed with the manufacture, for commercial purposes, of ABI’s
OBI-822 using Stellar cGMP grade KLH, then SBI and ABI will in good faith negotiate the terms of a KLH supply agreement, with the
best efforts to complete and sign that agreement at least three months prior to the delivery by SBI to ABI the first commercial
lot of Stellar cGMP grade KLH produced for ABI under GMP and meeting the ABI specification. ABI shall use any KLH formulations
and test articles provided by SBI hereunder exclusively for evaluation purposes and shall not use any such materials for commercial
purposes.

 

4.           Proprietary
Rights.

 

4.1           SBI/ABI
Intellectual Property. SBI and ABI shall retain ownership of all intellectual property presently owned by each, unless otherwise
agreed in this Agreement or in writing by both Parties. SBI shall retain all right, title and interest in Stellar KLH20-M, any
other KLH formulations and test articles provided by SBI hereunder, any precursors or components of any of the foregoing, and any
reformulations or improvements of any of the foregoing that are conceived of and/or reduced to practice for use as a KLH starting
material for OBI-822 or any ABI product during and as a result of the work conducted hereunder (collectively, “Stellar
Materials”).

 

4.2           Joint
Intellectual Property. Although it is not intended that SBI and ABI will jointly develop any intellectual property on test
article during the course of this collaboration hereunder, if any intellectual property is jointly developed, the Parties shall
attempt to negotiate ownership and licensing rights in good faith, depending on the technology being developed and the relative
interests and needs of the Parties. If no agreement can be reached on the allocation of ownership and licensing rights, then:

 

    	 	Page 4 of 10	 

     

    

  

a.           all
jointly conceived or developed Intellectual Property in or relating to Stellar Materials shall belong to SBI regardless of the
Party by whom such intellectual property was generated;

 

b.           all
jointly conceived or developed intellectual property in or relating to OBI-822 drug product shall belong to ABI regardless of the
Party by whom such intellectual property was generated; and

 

c.           any
other intellectual property that is jointly conceived or developed by SBI and ABI shall be jointly owned by SBI and ABI.

 

The Parties shall from time to time each
execute and deliver to the other assignments of intellectual property in order to effectuate the foregoing.

 

4.3           Nondisclosure.
SBI and ABI acknowledge and agree that each will have access to, become acquainted with, and receive confidential information of
the other in the course of performance of this collaboration hereunder. SBI and ABI hereby confirm and agree that the previously
signed mutual Nondisclosure Agreement attached hereto as Appendix C shall be included as part of this Agreement.

 

4.4           Collaboration
Data. Each Party shall use good scientific practices and shall comply in all material respects with applicable regulations
and customary good laboratory and clinical practices in the performance of the evaluation activities hereunder and under any Statement
of Work (including all data in the form required to be maintained under any applicable governmental regulations). Such records
shall comprise books, results, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs,
computer programs and documentation thereof, computer information storage means, samples of materials and other graphic or written
data generated in connection with such evaluation activities. Any such data developed by employees of SBI, or others on behalf
of SBI, shall be owned by SBI (“SBI Data”) and any such data developed by
employees of ABI, or others on behalf of ABI, shall be owned by ABI (“ABI Data”).
For purposes of evaluation of mutual performance of the objectives defined in the Statement of Work and to support regulatory filings,
each Party shall provide summaries of its Data, to the extent reasonably required. Each Party shall maintain such data in confidence
in accordance with Section 4.3 above and Appendix C hereto and shall not use such data
of the other Party except to the extent otherwise permitted by this Agreement or consented by the other Party.

 

4.5           No
Other Technology Rights. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party hereto,
as a result of this Agreement, obtain any ownership interest in. license rights to use, or other right to any technology, know-how,
patents, pending patent applications, compounds, products or biological materials of the other Party, including items owned, controlled
or developed by the other Party, or transferred by the other Party to said Party at any time pursuant to this Agreement. [Note:
Deleted for repetition in Section 4.2(a).]

 

    	 	Page 5 of 10	 

     

    

  

4.6           Warranties
and Representations. SBI and ABI each warrant and represent that:

 

a.           It
shall not make any unauthorized use of any patents, copyrights, trade secrets, confidential information, or any other intellectual
property of any third party in performing under this Agreement;

 

b.           It
shall own all rights, title and interest in and to the intellectual property, or it shall obtain valid and enforceable licenses
to the intellectual property.

 

c.           It
has the right, power and authority to enter into and perform this Agreement and, by entering into this Agreement, it will not constitute
a breach or default under any license, agreement, contract, arrangement, judgment, decree, order, law, regulation or permit.

 

4.7           Indemnification.
SBI and ABI shall each indemnify, defend and hold harmless the other Party and its affiliates, officers, directors, managers and
employees against any and all claims, suits, actions or threats of action, liabilities, settlement amounts, damages, expenses or
costs of any kind whatsoever, including without limitation reasonable attorneys' fees and costs, which directly result from or
arise out of (a) any material inaccuracy of any representations or warranties made by the indemnifying Party under this Agreement,
(b) the indemnifying Party's material breach or failure to perform any provision of this Agreement that it is required to perform
and remain uncured per Section 5.2 hereof, or (c) the gross negligence or intentional misconduct of the indemnifying Party.

 

5.           Termination
and Remedies.

 

5.1           Term.
This Agreement shall commence on the Effective Date. Unless earlier terminated in accordance with the provisions of this Agreement
or extended by a duly executed Statement of Work or other amendment of this Agreement that is executed by both Parties, this Agreement
shall continue in effect for twenty-four (24) months from the Effective Date. The expiration or earlier termination of this Agreement
shall not trigger the expiration or termination of any manufacture or supply agreement subsequently entered into between the Parties,
the terms of which agreement will be subject to its own provisions.

 

5.2           Termination
for Breach. Either Party may terminate this Agreement if the other Party materially breaches any of its duties or obligations
hereunder and such breach remains uncured for at least thirty (30) days after the non-breaching Party gives written notice of the
breach. Any such termination shall not constitute the sole remedy in the event of a breach.

 

5.3           No
Exclusive Remedy. Nothing in this Agreement is intended to limit any remedies available to either Party.

 

5.4           Survival.
The following Sections shall survive any expiration or termination of this Agreement: Sections 2.8, 2.10, 4.1 through 4.1 - 4.7,
5.3, 5.4, 6.1 and 7.1 through 7.11, and Appendix C.

 

    	 	Page 6 of 10	 

     

    

 

6.           Relationships.

 

6.1           Relationship.
Pursuant to the terms of this Agreement, SBI and ABI shall act in this collaboration as independent contractors. SBI and ABI shall
not be partners, of each other, and the collaboration shall not constitute a partnership, unincorporated association or any other
form of legal entity. No Party is authorized to, and shall not; enter into any contract or commitments in the name of, or on behalf
of, the other Party.

 

6.2           Business
Opportunities. Unless otherwise specified in this Agreement or any Statement of Work, SBI and ABI shall each be free to conduct
its own business and to pursue its own opportunities, regardless of any competition that may be created or furthered between the
Parties. Additionally, except as so specified, the Parties shall not have an obligation to disclose to the other any business opportunities
that may result from the activities generated by this Agreement or any Statement of Work.

 

6.3           Non-Transferability.
The Parties have carefully selected each other for this collaboration as a result of many factors including, without limitation,
technical expertise, credibility, integrity, reputation and business acumen. Therefore, subject to the Parties rights to engage
subcontractors pursuant to Section 2.11 hereof, no Party shall voluntarily or by operation of law, assign, hypothecate, give, transfer,
mortgage, or otherwise transfer or encumber all or any part of its rights, duties or other interests in this Agreement (collectively
“Assignment”), without the other Party’s prior written consent, which consent may be withheld at the sole
discretion of the non-assigning Party. Any attempt to make an Assignment in violation of this provision shall be a material breach
of this Agreement and any Assignment in violation of this provision shall be null and void. Notwithstanding the foregoing, this
Agreement shall be assignable as part of a bona fide transfer of all or substantially all of the assets or stock of a Party, or
a merger in which the Party is not the surviving entity.

 

7.           General
Provisions.

 

7.1           Export.
Each Party shall comply with all applicable laws, regulations and restrictions of the United States concerning the export of products,
technical data and direct products thereof including, without limitation, all regulations regarding export, asset control and destination
control of the Commerce, Treasury, State and Defense Departments of the United States Government, and the Export Administration
Act of 1979, as amended from time to time.         

 

7.2           Amendment.
No amendment or modification of this Agreement shall be binding on any of the Parties unless it is in writing and signed by each
of the Parties hereto at the time of the modification.

 

7.3           Successors.
Without limiting any restrictions on assignment contained in this Agreement, each and all of the provisions hereof shall be binding
on and inure to the benefit of the Parties hereto and their respective successors and permitted assigns.

 

7.4           Dispute
Resolution. If any dispute arises between the Parties relating to the validity, construction, enforceability, or performance
of this Agreement, the aggrieved Party shall notify the other Party in writing of such dispute. If, within thirty (30) days after
such notice is deemed to have been received, the Parties have not succeeded in negotiating a resolution of the dispute, either
Party shall be free to proceed to arbitration the arbitration shall be conducted pursuant to the Commercial Arbitration Rules of
the American Arbitration Association. The Arbitrator shall, in rendering its decision, apply the substantive law of the State of
California without regard to its conflict of laws provisions, except that the interpretation of an enforcement of this section
shall be governed by the United States Federal Arbitration Act.

 

    	 	Page 7 of 10	 

     

    

  

7.5           Warranty
Limitation. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY, AND EACH PARTY EXPRESSLY DISCLAIMS
ALL DISCLAIMS, ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT
TO ANY COMPOUNDS OR OTHER BIOLOGICAL OR CHEMICAL MATERIALS OR INFORMATION PROVIDED TO THE OTHER PARTY PURSUANT TO THIS AGREEMENT.

 

7.6           Entire
Agreement. This Agreement and Appendices A, B-X, C constitute the entire agreement between the Parties.
There are no verbal representations between or among the Parties that are being relied upon by either of the Parties other than
those expressly set forth in this Agreement.

 

7.7           Notices.
All notices required to be given under this Agreement must be made in writing by (i) first-class mail, postage prepaid, certified,
return receipt, (ii) by regularly scheduled commercial delivery service, Federal Express or equivalent, (iii) by facsimile
followed immediately by first-class mail, or (iv) by personal delivery. Such notices will be deemed given five business days
after deposit with the postal service, three business days after deposit with the commercial carrier, or on the day of personal
delivery.

 

7.8           Severability.
If any term or provision of this Agreement is determined to be illegal, unenforceable, or invalid in whole or in part for any reason,
such illegal, unenforceable, or invalid provisions or part thereof shall be stricken from this Agreement, and such provision shall
not affect the legality, enforceability, or validity of the remainder of this Agreement.

 

7.9           Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

7.10         Waiver.
Any waiver must be in writing. No waiver of any provision or consent to any action shall constitute a waiver of any other provision
or consent to any other action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or
commit a Party to provide a waiver in the future except to the extent specifically set forth in writing. Any waiver given by a
Party shall be null and void if the Party requesting such waiver has not provided a full and complete disclosure of all material
facts relevant to the waiver requested.

 

7.11         Time
of Essence. For purposes of this Agreement, time is of the essence.

 

    	 	Page 8 of 10	 

     

    

  

IN WITNESS WHEREOF,
each of the Parties hereto have executed this Agreement as of the date first set forth above.

 

	Amaran Biotechnology, Inc.	 	Stellar Biotechnologies, Inc.
	 	 	 
	By:	/s/ Tessie Che	 	By:	/s/ Frank Oakes
	 	Tessie Che	 	 	Frank Oakes
	 	General Manager	 	 	Chief Executive Officer

 

    	 	Page 9 of 10	 

     

    

 

Appendix A

 

Table of Contents of Statement of Work

 

To Collaboration Agreement

 

	Appendix B-X	 	Project Title
	Appendix B-1	 	Evaluation of 3 lots of subunit KLH for comparability study at OBI (Stellar KLH 20M)
	Appendix B-2	 	Reference Standard KLH Dimer (Aquaculture)
	Appendix B-3	 	Reference Standard KLH-1 Dimer (Aquaculture)
	Appendix B-4	 	Reference Standard KLH-2 Dimer (Aquaculture)

 

    	 	Page 10 of 10Exhibit 4.5

 

 

 

GLOBAL PARTNERS LP,

 

GLP FINANCE CORP.

 

AND

 

THE GUARANTORS NAMED ON THE SIGNATURE PAGES HEREOF

 

 

7.000% SENIOR NOTES DUE 2023

 

 

FIRST SUPPLEMENTAL INDENTURE

 

Dated as of September 9, 2015

 

 

DEUTSCHE BANK TRUST COMPANY AMERICAS

 

As Trustee

 

 

 

 

THIS FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of September 9, 2015, is entered into between Global Partners LP, a Delaware limited partnership (the “Partnership”), GLP Finance Corp., a Delaware corporation (“Finance Corp.” and together with the Partnership, the “Issuers”), Global Operating LLC, a Delaware limited liability company (“Global Operating”), Global Companies LLC, a Delaware limited liability company (“Global Companies”), Glen Hes Corp., a Delaware corporation (“Glen Hes”), Global Montello Group Corp., a Delaware corporation (“Global Montello”), Chelsea Sandwich LLC, a Delaware limited liability company (“Chelsea Sandwich”), Global Energy Marketing LLC, a Delaware limited liability company (“GEM”), Global Energy Marketing II LLC, a Delaware limited liability company (“GEM II”), Global CNG LLC, a Delaware limited liability company (“CNG”), Warren Equities, Inc., a Delaware corporation (“WEI”), Maryland Oil Company, Inc., a Delaware corporation (“Maryland Oil”), Alliance Energy LLC, a Massachusetts limited liability company (“Alliance”), Bursaw Oil LLC, a Massachusetts limited liability company (“Bursaw”), Drake Petroleum Company, Inc., a Massachusetts corporation (“Drake”), Cascade Kelly Holdings LLC, an Oregon limited liability company (“Cascade Kelly”), Global Partners Energy Canada ULC, an Alberta unlimited liability corporation (“Global Canada”), Warex Terminals Corporation, a New York corporation (“Warex”), and Puritan Oil Company, Inc., a New Jersey corporation (“Puritan Oil” and, together with Global Operating, Global Companies, Glen Hes, Global Montello, Chelsea Sandwich, GEM, GEM II, CNG, WEI, Maryland Oil, Alliance, Bursaw, Drake, Cascade Kelly, Global Canada and Warex, the “Guarantors”), and Deutsche Bank Trust Company Americas, as Trustee (the “Trustee”).  The Issuer and the Trustee agree as follows for the benefit of the holders (the “Holders”) of the 7.000% Notes due 2023 of the Issuers (the “Notes”):

 

WHEREAS, the Issuers, the Guarantors and the Trustee are parties to that certain Indenture dated as of June 4, 2015 (the “Original Indenture”), relating to the Notes;

 

WHEREAS, Section 9.01(d) of the Original Indenture provides that the Issuers, the Guarantors and Trustee, without the consent of the Holders, may amend or supplement the Original Indenture to make any change that would provide any additional rights or benefits to the Holders of the Notes or that does not adversely affect the legal rights hereunder of any such Holder, provided that any change to conform this Indenture to the Offering Memorandum shall not be deemed to adversely affect such legal rights;

 

WHEREAS, the Issuers and the Guarantors desire and have requested the Trustee to join with them in entering into this Supplemental Indenture for the purpose of amending the Indenture in certain respects as permitted by Section 9.01(d) of the Original Indenture;

 

WHEREAS, the Issuers and the Guarantors have determined that Global Operating was inadvertently omitted from the signature page of the Original Indenture as a guarantor of the Notes, which resulted in the definition of the “Guarantors” in the Original Indenture being inconsistent with the definition of the same, contained in the Offering Memorandum;

 

WHEREAS, the Issuers have delivered to the Trustee simultaneously with the execution and delivery of this Supplemental Indenture an Officers’ Certificate and Opinion of Counsel relating to this Supplemental Indenture as contemplated by Sections 11.04 and 11.05 of the Original Indenture; and

 

1

 

WHEREAS, all acts and requirements necessary to make this Supplemental Indenture the legal, valid and binding obligation of the Issuers and the Guarantors have been done.

 

NOW, THEREFORE, in consideration of the above premises, each party hereby agrees, for the benefit of the Holders as follows:

 

ARTICLE I

 

AMENDMENTS TO INDENTURE

 

Section 1.1            Amendment to Signature Page.  The signature page of the Original Indenture is hereby replaced in its entirety with the signature page to this Supplemental Indenture, which includes Global Operating as a guarantor.

 

Section 1.2            Definition of Guarantors.  For the avoidance of doubt, the term Guarantors shall refer to the parties listed as “Guarantors” on the signature page to this Supplemental Indenture and shall include Global Operating.

 

ARTICLE II

 

MISCELLANEOUS PROVISIONS

 

Section 2.1            Defined Terms.  For all purposes of this Supplemental Indenture, except as otherwise defined or unless the context otherwise requires, terms used in capitalized form in this Supplemental Indenture and defined in the Original Indenture have the meanings specified in the Original Indenture.

 

Section 2.2            Indenture.  Except as amended hereby, the Original Indenture and the Notes are in all respects ratified and confirmed and all the terms shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Original Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered under the Original Indenture shall be bound hereby and all terms and conditions of both shall be read together as though they constitute a single instrument, except that in the case of conflict the provisions of this Supplemental Indenture shall control.

 

Section 2.3            New York Law to Govern.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

 

Section 2.4            Effect of Headings.  The Article and Section headings herein are for convenience only and shall not affect the construction hereof.

 

Section 2.5            Counterparts.  This Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original; but such counterparts shall together constitute but one and the same instrument.

 

Section 2.6            Severability.  In case any one or more of the provisions in this Supplemental Indenture or in the Notes shall be held invalid, illegal or unenforceable, in any

 

2

 

respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions shall not in any way be affected or impaired thereby, it being intended that all of the provisions hereof shall be enforceable to the full extent permitted by law.

 

Section 2.7            Effectiveness.  The provisions of this Supplemental Indenture shall be effective only upon execution and delivery of this instrument by the parties hereto.

 

Section 2.8            The Trustee.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Issuers and the Guarantors.

 

[Signature pages follow.]

 

3

 

	
 
    	
SIGNATURES
    
	
 
    	
 
    
	
 
    	
GLOBAL PARTNERS LP
    
	
 
    	
 
    
	
 
    	
By: 
    	
Global GP LLC, its   General Partner
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Name: Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Title: Chief Financial   Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
GLP FINANCE CORP.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Daphne H. Foster
    
	
 
    	
 
    	
Name: Daphne H. Foster
    
	
 
    	
 
    	
Title: Chief Financial   Officer
    

 

[SIGNATURE PAGE—FIRST SUPPLEMENTAL INDENTURE]

 

 

	
 
    	
GUARANTORS
    
	
 
    	
 
    
	
 
    	
GLOBAL COMPANIES LLC
    
	
 
    	
GLOBAL ENERGY MARKETING   LLC
    
	
 
    	
CHELSEA SANDWICH LLC
    
	
 
    	
ALLIANCE ENERGY LLC
    
	
 
    	
GLOBAL ENERGY MARKETING   II LLC
    
	
 
    	
CASCADE KELLY HOLDINGS   LLC
    
	
 
    	
GLOBAL CNG LLC
    
	
 
    	
 
    
	
 
    	
By: 
    	
Global Operating LLC,
    
	
 
    	
 
    	
its Sole Member
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
Global Partners LP,
    
	
 
    	
 
    	
its Sole Member
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
Global GP LLC,
    
	
 
    	
 
    	
its General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Name: Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Title: Chief Financial   Officer
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
BURSAW OIL LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
Alliance Energy LLC,
    
	
 
    	
 
    	
its Sole Member
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
Global Operating LLC,
    
	
 
    	
 
    	
its Sole Member
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
Global Partners LP,
    
	
 
    	
 
    	
its Sole Member
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
Global GP LLC,
    
	
 
    	
 
    	
its General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Name: Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Title: Chief Financial   Officer
    

 

[SIGNATURE PAGE—FIRST SUPPLEMENTAL INDENTURE]

 

 

	
 
    	
GLOBAL MONTELLO GROUP   CORP.
    
	
 
    	
GLEN HES CORP.
    
	
 
    	
WARREN   EQUITIES, INC.
    
	
 
    	
WAREX TERMINALS   CORPORATION
    
	
 
    	
DRAKE PETROLEUM   COMPANY, INC.
    
	
 
    	
PURITAN OIL   COMPANY, INC.
    
	
 
    	
MARYLAND OIL   COMPANY, INC.
    
	
 
    	
GLOBAL PARTNERS ENERGY   CANADA ULC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Daphne H. Foster
    
	
 
    	
 
    	
Name: Daphne H. Foster
    
	
 
    	
 
    	
Title: Chief Financial   Officer
    
	
 
    	
 
    
	
 
    	
GLOBAL OPERATING LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
Global Partners LP, its   Sole Member
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
Global GP LLC, its   General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Name: Daphne H. Foster
    
	
 
    	
 
    	
 
    	
Title: Chief Financial   Officer
    

 

[SIGNATURE PAGE—FIRST SUPPLEMENTAL INDENTURE]

 

 

	
 
    	
DEUTSCHE BANK TRUST   COMPANY
    
	
 
    	
AMERICAS, as Trustee
    
	
 
    	
 
    
	
 
    	
By:
    	
DEUTSCHE BANK NATIONAL   TRUST COMPANY
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Robert S. Peschler
    
	
 
    	
 
    	
 
    	
Name: Robert S.   Peschler
    
	
 
    	
 
    	
 
    	
Title: Vice President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Linda Reale
    
	
 
    	
 
    	
 
    	
Name: Linda Reale
    
	
 
    	
 
    	
 
    	
Title: Vice President
    

 

[SIGNATURE PAGE—FIRST SUPPLEMENTAL INDENTURE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]